title: [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
abstract: The tumor lysis syndrome (TLS) is a metabolic disorder resulting from a massive tumor breakdown. It is characterized by hyperuricemia, hyperphosphatemia, hypocalcemia and hyperkalemia and predisposes to acute renal failure. TLS usually occurs after the initiation of cytotoxic therapy and is more frequent in the case of neoplasias with a high proliferative rate or that are highly chemo-sensitive. We report the case of a man with a recurrent kidney cancer who presented with a TLS and acute renal failure after initiation of sunitinib.
authors.affiliation: Sección Nefrología, Departamento de Medicina Interna, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina.
authors.forename: Ezequiel
authors.initials: E
authors.lastname: Rodríguez-Reimúndes
authors.forename: Florencia
authors.initials: F
authors.lastname: Perazzo
authors.forename: Antonio R
authors.initials: AR
authors.lastname: Vilches
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D017809:Fatal Outcome; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib; D015275:Tumor Lysis Syndrome / Q000209:etiology*
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib